NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.vrtx.comVertex Pharmaceuticals Inc's patent US8629162 for SYMDEKO, a product that modulates ATP-Binding Cassette transporters for treating cystic fibrosis, is set to expire on June 24, 2025. This expiration may allow for increased competition as generic versions of the drug could enter the market, impacting Vertex's revenue from this product.
PatentVertex Pharmaceuticals Inc's patent US8629162 for ALYFTREK is set to expire on June 24, 2025. This patent covers modulators of ATP-Binding Cassette transporters, including treatments related to cystic fibrosis. The expiration may open the market to generic competition, potentially impacting Vertex's revenue associated with ALYFTREK.
Patent ExpiryPatent US8629162 for KALYDECO, a drug used to treat cystic fibrosis, is set to expire on June 24, 2025. The patent covers modulators of ATP-Binding Cassette transporters, including treatments for diseases caused by these transporters. As such patents expire, generic competition may emerge, potentially impacting Vertex Pharmaceuticals Inc.'s revenue and market position.
Patent ExpiryVertex Pharmaceuticals Incorporated announced the retirement of Stuart A. Arbuckle, its Chief Operating Officer (COO), effective July 1, 2025. Charles F. Wagner, Jr. will assume the role of COO and remain the Executive Vice President and Chief Financial Officer, while Duncan J. McKechnie will take on the position of Chief Commercial Officer. Both appointments take effect on the same date. Wagner has been CFO since April 2019, and McKechnie has over 30 years of industry experience, contributing significantly to the launch of the company's cystic fibrosis drugs and recent innovations in cell and gene therapies. The transitions are expected to maintain stability within Vertex as it continues to advance its therapeutic offerings.
Leadership ChangeThe expiry of Patent US8354427 for ALYFTREK, a treatment that modulates ATP-Binding Cassette (ABC) transporters for ABC transporter-mediated diseases, is set for July 6, 2026. This patent, assigned to Vertex Pharmaceuticals Inc, plays a crucial role in the protection of intellectual property related to the treatment. The expiration may open the market to generic alternatives, potentially impacting Vertex's sales and market share for the product.
Patent ExpiryVertex Pharmaceuticals Inc. will see the expiration of Patent US8354427 on July 6, 2026, related to its cystic fibrosis treatment, TRIKAFTA, which is copackaged. This patent pertains to modulators of ATP-Binding Cassette (ABC) transporters, including methods for treating diseases related to these transporters. The expiration may allow generic competition, impacting Vertex's market position and revenue from TRIKAFTA.
patent expirationThe patent US8354427 for KALYDECO, a medication developed by Vertex Pharmaceuticals Inc targeting cystic fibrosis through modulating ABC transporters, is set to expire on July 6, 2026. This expiration may impact the company's market exclusivity and potential revenue streams from KALYDECO, as generic alternatives could enter the market following patent expiration.
Patent ExpirationThe patent US8354427 for the SYMDEKO product, which modulates ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis, will expire on July 6, 2026. The expiration may impact Vertex Pharmaceuticals Inc's market position, as generics could enter the market following the patent's lapse, potentially affecting revenue from SYMDEKO.
Patent ExpirationThe U.S. patent US7973038 related to Vertex Pharmaceuticals Inc's ORKAMBI is set to expire on November 8, 2026. This patent covers compounds used as modulators of ATP-Binding Cassette transporters, including the Cystic Fibrosis Transmembrane Conductance Regulator, highlighting its significance in treating diseases associated with these transporters. The expiration of this patent may open the market to generic alternatives, potentially impacting Vertex's revenue from ORKAMBI.
Patent ExpirationThe patent US9670163 for KALYDECO, assigned to Vertex Pharmaceuticals Inc, is set to expire on December 28, 2026. KALYDECO is a cystic fibrosis treatment that utilizes a compound designed to enhance lung function in patients with specific genetic mutations. The expiration of this patent may expose Vertex to generic competition, potentially impacting its market share and revenue from this product.
patent expiration